The Cancer Consortium

Cancer News & Information Center

Sunday, October 25th, 2026

Menu

  • Home
  • Members
    • Travera
    • Soligenix (SNGX)
    • NuView Life Sciences
  • News
    • MEMBER NEWS
    • FINDINGS
    • INDUSTRY
  • INTERVIEWS
    • CEOs
    • KOLs
  • Cancer Types
    • Breast Cancer
    • Cervical Cancer
    • Head and Neck Cancer
  • Database
  • About
    • Altru Cancer
    • Cancer Consortium
    • Newsletter
    • Research
  • RESOURCES
    • Foundations
    • Patient Resources
    • Media Resources

Quintessence Biosciences’ Novel Approach to Cancer Therapy

By Global Cancer Consortium on February 17, 2010 • ( Leave a comment )

Quintessence Biosciences is a biopharmaceutical company specializing in the development of novel protein-based therapeutics to fight cancer.

The Universal Vaccines of Inovio Biomedical

By Global Cancer Consortium on February 11, 2010 • ( Leave a comment )

Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.

TapImmune Taps Into Cancer Defense

By Global Cancer Consortium on February 9, 2010 • ( Leave a comment )

How do cancer cells evade the immune system, growing undetected until they’re discovered as a tumor?

[OneMedForum] Clarient Grows Along with Cancer Testing Market

By Global Cancer Consortium on February 6, 2010 • ( Leave a comment )

The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.

[OneMedForum] Alexza Pharmaceuticals’ Pipeline Is Built for Speed

By Global Cancer Consortium on February 4, 2010 • ( Leave a comment )

Alexza Pharmaceuticals of Mountain View, Calif., is focused on the development of inhalation drugs for the treatment of central nervous system disorders.

[OneMedForum] Senesco Technologies: Life and Death on a Cellular Level

By Global Cancer Consortium on February 4, 2010 • ( Leave a comment )

“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.

[OneMedForum] Micrus Endovascular: Help for Stroke Patients

By Global Cancer Consortium on February 3, 2010 • ( Leave a comment )

Micrus Endovascular is the only publicly traded company focused on strokes.

Diabetes Drug Wins Approval, Helps the Competition

By Global Cancer Consortium on January 29, 2010 • ( Leave a comment )

The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.

Posts navigation

‹ Newer 1 … 56 57 58 59 60 61 62 63 64 65 66 … 84 Older ›

INTERVIEWS »

INTERVIEW: Travera CEO Clifford Reid PhD

INTERVIEW: Soligenix CEO Christopher Schaber PhD.

INTERVIEW: Biden Cancer Initiative’s Greg Simon

PROFILES »

Gray Scale Images Convert to Detailed Color Images to Better Diagnose Breast Cancer

New Technology Using Light Therapy Kills Cells with No Side Effects

Real-time, In vivo Imaging Platform to Guide Surgeon During Cancer Surgery

Image result for cancer commons

Cancer Progress Report

Altru Cancer Progress Report June 2019

Subscribe to Cancer Progress Report

 

 

About Cancer Consortium

Members of the Global Cancer Consortium believe that progress occurs through collaboration which can occur through improved information.

This news site aggregates information and profiles of the member companies and organizations.

Its Cancer Progress Report reaches thousands of investors and industry professionals.

Global Cancer Consortium

The Cancer Consortium was formed by the Altru Cancer Project to offer one place to learn about the most promising developments, technologies and companies focused on Cancer.

 

 

  • Top categories: COMPANIES / cancer / Blog / feature2 / NEWS / Featured Articles / MEMBER NEWS / feature1 / Uncategorized / Member Spotlight
  • Top tags: cancer / breast cancer / diagnostics / oncology / prostate cancer / clarient / peter winter / brain cancer / melanoma / immunotherapy
Proudly powered by WordPress | Theme: Broadsheet by Pro Theme Design.